产能建设稳步推进，研发创新硕果盈枝。25H1，南通2 期2.4 万平方米设施已取得实验动物使用许可 证，进入GLP 模拟运营阶段，有望于26 年初开启产能爬坡。同位素设施1800 平方米实验室扩建改造和 黄山益诺思新建综合实验楼正在推进中；此外，公司加大创新投入，25H1 研发投入营收占比达5.9%， 同比+2.3pct，已完成α核素资质认证和关键评价技术探索、肿瘤类器官建设和AI 病理诊断模型的搭建， 同时不断推进AI 在非临床研究报告、翻译、阅片领域的应用，提升新药研发效率。 盈利预测与投资建议 根据25 年中报，我们下调收入和毛利率预测、上调费用预测，调整2025-2027 年每股收益预测为 0.14/0.94/1.41（原预测25-27 年为0.99/1.16/1.42）元，根据可比公司给予26 年46 倍PE，对应目标价 43.24 元，维持"买入"评级。 风险提示 核心观点 事件：25H1 公司实现收入3.8 亿元，同比-38.0%，归母净利润-1519 万元，同比-115.9%，扣非归母净利 润-3256 万元，同比-136.4%。 需求放缓拖累业绩，静待拐点出现。上半年公司业绩下滑主要受国内投 ...

Core Viewpoint - Yinosh experienced a slight increase in stock price on September 11, with a trading volume of 63.42 million yuan, indicating ongoing market activity despite financial challenges [1] Group 1: Financial Performance - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, representing a year-on-year decrease of 38.04% [2] - The company recorded a net profit attributable to shareholders of -15.19 million yuan, a significant decline of 115.88% compared to the previous period [2] Group 2: Shareholder and Market Activity - As of June 30, 2025, Yinosh had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average number of circulating shares per shareholder increased by 0.91% to 5,235 shares [2] - On September 11, Yinosh's financing buy-in amounted to 4.74 million yuan, with a net financing buy of -1.48 million yuan, indicating more repayments than new purchases [1] - The total balance of margin trading for Yinosh reached 87.06 million yuan, accounting for 2.45% of its market capitalization [1] Group 3: Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included ICBC Medical Health Stock, which increased its holdings by 72,300 shares to 439,400 shares [3] - New entrants among the top ten shareholders included ICBC Strategic Transformation Stock and Harvest Medical Health Stock, holding 354,100 shares and 344,300 shares respectively [3] - Notably, several funds such as Agricultural Bank Medical Health Stock and others exited the top ten circulating shareholders list [3]

Group 1 - On September 10, Yinos achieved a stock price increase of 3.57% with a trading volume of 79.4568 million yuan, and the net financing purchase amounted to 3.0738 million yuan [1] - As of September 10, the total balance of margin trading for Yinos was 88.5422 million yuan, which represents 2.51% of its circulating market value [1] - Yinos primarily operates in the field of biopharmaceutical non-clinical research services, with 96.31% of its revenue coming from non-clinical services [1] Group 2 - As of June 30, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - For the first half of 2025, Yinos reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - After its A-share listing, Yinos has distributed a total of 45.1135 million yuan in dividends [2]

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder structure [1][2][3] - As of September 2, Yinosh's stock price fell by 2.24%, with a trading volume of 58.6354 million yuan. The net financing buy was -3.902 million yuan, indicating a higher repayment than new purchases [1] - Yinosh's financing balance reached 86.1492 million yuan, accounting for 7.59% of its market capitalization, with no short selling activity reported on the same day [1] Group 2 - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - As of June 30, 2025, the number of Yinosh shareholders was 5,386, a decrease of 0.90%, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - Yinosh has distributed a total of 45.1135 million yuan in dividends since its A-share listing, with changes in institutional holdings noted among its top shareholders [3]

Company Overview - Yinos Biotech Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company is set to be listed on September 3, 2024. Its main business involves providing comprehensive research and development services (CRO) focused on non-clinical research services in the biopharmaceutical sector [1] - The revenue composition of Yinos is as follows: non-clinical services account for 95.42%, clinical services for 4.11%, and other services for 0.47% [1] Stock Performance - On September 1, Yinos shares increased by 5.1%, reaching a price of 40.98 CNY per share, with a trading volume of 30.95 million CNY and a turnover rate of 2.75%. The total market capitalization is 5.777 billion CNY [1] Shareholder Information - Among the top ten circulating shareholders of Yinos, one fund from Harvest Fund Management, the Harvest Medical Health Stock A (005303), entered the top ten in the second quarter, holding 344,300 shares, which represents 1.22% of the circulating shares. The estimated floating profit for today is approximately 685,200 CNY [2] - The Harvest Medical Health Stock A fund was established on December 4, 2017, with a current size of 786 million CNY. Year-to-date returns are 42.3%, ranking 534 out of 4222 in its category. Over the past year, returns are 50.75%, ranking 1765 out of 3779, and since inception, the fund has achieved a return of 93.9% [2] Fund Management - The fund manager for Harvest Medical Health Stock A is Sun Xiaohui, who has been in position for 144 days, with a total fund size of 985 million CNY. The best return during his tenure is 37.64%, while the worst is 37.22% [3] - The other fund manager, Hao Miao, has been in position for 6 years and 230 days, managing a total fund size of 3.652 billion CNY. His best return during his tenure is 183.83%, while the worst is -30.4% [3]

Summary of Key Points Core Viewpoint - Next week, 29 stocks in the A-share market will face a lock-up expiration, with a total of 2.013 billion shares being unlocked, amounting to a market value of approximately 18.877 billion yuan, representing a week-on-week decrease of 73.51% [1][2]. Company-Specific Summaries - **Foton Motor**: The largest stock by market value to be unlocked next week, with an unlock value of 3.957 billion yuan and 1.429 billion shares set to be released on September 3, 2025. The shares are from a targeted placement to institutional investors at an issue price of 2.10 yuan per share [2][4]. - **Futian Technology**: The second-largest unlock value at 2.887 billion yuan, with 0.079 billion shares to be released on September 4, 2025. The shares include original shareholders' restricted shares and strategic placement shares [2][4]. - **Yinose**: The third-largest unlock value at 2.437 billion yuan, with 0.062 billion shares to be released on September 3, 2025, also consisting of original shareholders' restricted shares and strategic placement shares [2][4]. Market Performance - As of August 29, 2023, the stock price of Foton Motor was 2.77 yuan per share, with a market capitalization of approximately 21.9 billion yuan. The stock has seen a return of over 30% since the targeted placement, resulting in a floating profit of over 900 million yuan for the major shareholder, Beijing Automotive Group [4]. - Futian Technology's stock price was 36.63 yuan per share, with a market capitalization of about 5.7 billion yuan. Since its listing, the stock has appreciated over 260% compared to its issue price, indicating significant gains for strategic placement shareholders [4]. Unlocking Impact - Six stocks will see their unlock quantities exceed 30% of their total share capital, including Futian Technology (50.71%), Yinose (44.33%), Wufangzhai (37.61%), Sudar (36.76%), Liren Technology (34.81%), and Aopumai (31.83%). The unlocking will lead to a substantial increase in their circulating shares, with four stocks experiencing an increase of over 100% in their circulating market [7][8].

Core Viewpoint - Next week, 29 stocks in the A-share market will face a lock-up expiration, with a total of 2.013 billion shares being unlocked, amounting to a market value of 18.877 billion yuan, which represents a week-on-week decrease of 73.51% [1][3]. Summary by Category Unlocking Stocks - The stocks with the highest unlocking market value include Foton Motor at approximately 4 billion yuan, Fute Technology at 2.887 billion yuan, and Yinos at 2.437 billion yuan [2][3]. - Foton Motor will unlock 1.429 billion shares on September 3, 2025, all from a targeted placement to institutional investors [3][5]. - Fute Technology will unlock 0.079 billion shares on September 4, 2025, consisting of original shareholders' restricted shares and strategic placement shares [3][5]. - Yinos will unlock 0.062 billion shares on September 3, 2025, also from original shareholders' restricted shares and strategic placement shares [3][5]. Market Performance - As of August 29, the stock price of Foton Motor was 2.77 yuan per share, with a market capitalization of approximately 21.9 billion yuan [6]. - The stock price of Fute Technology was 36.63 yuan per share, with a market capitalization of about 5.7 billion yuan [6]. - The stock performance for the month of August shows Foton Motor with a gain of 2.97%, Fute Technology with a gain of 7.04%, and Yinos with a decline of 13.12% [3]. Increase in Circulation - Among the 29 stocks facing unlocking, six stocks will see their circulation increase by more than 30%, including Fute Technology (50.71%), Yinos (44.33%), Wufangzhai (37.61%), Suda Shares (36.76%), Liren Technology (34.81%), and Aopumai (31.83%) [10][11]. - Four of these stocks will experience a circulation increase of over 100% after the unlocking [10].

Group 1 - The core viewpoint of the report indicates a significant decline in the company's financial performance for the first half of 2025 compared to the same period in 2024, with a notable drop in revenue and net profit [2][3]. - Total assets at the end of the reporting period amounted to approximately 3.21 billion RMB, showing a slight decrease of 0.20% from the previous year [2]. - The company's operating income was reported at approximately 375.23 million RMB, reflecting a decrease of 38.04% year-on-year [2]. Group 2 - The total profit for the period was approximately 536.15 thousand RMB, which represents a drastic decline of 99.49% compared to the previous year [2]. - The net profit attributable to shareholders was reported as a loss of approximately 15.19 million RMB, marking a decrease of 115.88% from the same period last year [2]. - The company’s research and development expenditure as a percentage of operating income increased to 5.94%, up by 2.27 percentage points from the previous year [2]. Group 3 - The weighted average return on equity decreased to -0.64%, down by 6.37 percentage points compared to the previous year [2]. - The basic and diluted earnings per share were both reported at -0.11 RMB, a decline of 112.22% from the previous year [2]. - The total number of shareholders at the end of the reporting period was 5,386 [2].

Meeting Information - The shareholder meeting is scheduled for September 23, 2025, at 14:30 [1] - The meeting will be held at the Center Report Hall, 199 Guoshoujing Road, China (Shanghai) Pilot Free Trade Zone [1] - Voting will be conducted through both on-site and online methods [1] Voting Procedures - The online voting system will be the Shanghai Stock Exchange's shareholder meeting online voting system [1] - Voting will be available from 9:15 to 15:00 on the day of the meeting [1] - Shareholders can vote via the trading system or the internet voting platform [2][3] Shareholder Participation - Only shareholders registered by the close of trading on September 15, 2025, are eligible to attend the meeting [5] - Shareholders can appoint proxies to attend and vote on their behalf [4][5] Meeting Registration - Shareholders must register in advance to attend the meeting [5][6] - Registration requires identification and proof of shareholding [6] Additional Information - The company will provide reminder services to facilitate participation from small and medium investors [3] - Transportation and accommodation costs for attending shareholders are self-funded [6]

Group 1 - The third meeting of the supervisory board of Shanghai Yinos Biotech Co., Ltd. was held on August 27, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report, affirming that the report accurately reflects the company's operational management and financial status for the first half of 2025 [1][2] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations and that there were no misrepresentations or omissions [2][4] Group 2 - The supervisory board agreed to the proposal for the reappointment of the accounting firm, which will be submitted for approval at the company's third extraordinary general meeting of shareholders in 2025 [3] - The board approved the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and increase returns on cash assets, while ensuring the protection of shareholder interests [3][4]